Pozen licenses serotonin (5HT2B) receptor antagonist MT-500 from Roche. Privately-held Pozen is pursuing a "license-back" strategy, in-licensing products from pharmaceutical companies to assume clinical development with the goal of licensing the products back to the innovator for marketing. The Chapel Hill, N.C. company expects to begin Phase II trials of MT-500 in 2000
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth